Skip to content

Feasibility of lymphoscintigraphy and sentinel node biopsy in patients with renal cell carcinoma

Feasibility of lymphoscintigraphy and sentinel node biopsy in patients with renal cell carcinoma - Sentinel node procedure in kidney cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON30718
Enrollment
10
Registered
2009-02-27
Start date
2007-03-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney cancer renal cell carcinoma

Interventions

On the day before surgery or at least four hours pre-operatively, 99mTc-nanocolloid will be injected at the primary tumour site. The injection will be performed percutaneously under ultrasound or CT

Sponsors

Antoni van Leeuwenhoek Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Localized parenchymal tumor of the kidney not exceeding 10 cm (cT1-cT2) 2. No metastatic disease on imaging and clinical examination (cN0, cM0) 3. Age: 18 to 65 years 4. Life expectancy > 3 months 5. WHO performance status 0 or 1 and fit for surgery 6. Written informed consent obtained from the patient after having been informed about the objectives of the study and the medication used. 7. Blood counts: Leucocytes > 3.0 x 109/l, platelets > 100 x 109/l, hemoglobin > 6.0 mmol/l. 8. Serum bilirubin, ASAT, ALAT and creatinin within 1.5 times of upper limit of reference values of laboratory. 9. No prior systemic treatment with biological response modifiers, tyrosine-kinase inhibitors, monoclonal antibodies or chemotherapy.

Exclusion criteria

Exclusion criteria: 1. Parenchymal kidney tumor larger than 10 cm 2. clinically metastatic disease or at imaging 3. Patients in whom surgery is no option due to comorbidity 4. Current cardiovascular disease, hematopoetic, pulmonary, hepatic or renal dysfunction or WHO performance status > 1. 5. Previous immunotherapy, therapy with tyrosine-kinase inhibitors, monoclonal antibodies or chemotherapy. 6. Corticosteroid and/ or other immunosuppressive therapies. 7. Prior malignancies. In case of NED the period should be > 5 years. 8. Pregnancy

Design outcomes

Primary

MeasureTime frame
Feasibility of a) preoperative lymphoscintigraphy and b) intraoperative detection and sampling of the sentinel node.

Secondary

MeasureTime frame
Excised sentinel nodes will be examined for activation and/or downregulation of immune cells in comparison to non-sentinel nodes.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)